Literature DB >> 18537772

New avenue of research: antiepileptic drug and estradiol neuroprotection in epilepsy.

Libor Velísek1, Jana Velísková.   

Abstract

Current epilepsy therapy is symptomatic using antiepileptic drugs. This therapy suppresses seizures but does not prevent or cure epilepsy. Treatment strategies that could interfere with the process leading to epilepsy (epileptogenesis) would have significant benefits over the current approach. Neuronal damage contributing to restructuralization of the neuronal networks (especially in the hippocampus during temporal lobe epilepsy) is one of the significant components of ongoing epileptogenesis. Thus, treatment strategies alleviating seizure induced neuronal damage may become significant players against the deteriorating process of epileptogenesis. Current antiepileptic drugs, especially valproic acid, have some neuroprotective potential. However, frequently this potential is either insufficient or the side effects of long-term therapy cancel out the benefits. The attention is therefore aimed at different classes of drugs with already established neuroprotective potential. Steroid hormones are under investigation, especially two groups of these compounds: beta-estradiol and the selective estrogen receptor modulators--SERM. In low doses, beta-estradiol has neuroprotective potency in neurodegenerative diseases. However, its use in seizure-induced neuroprotection is confounded by the common perception of proconvulsant features of estrogens. Here, we review that both proconvulsant and neuroprotective features apply only under specific conditions and may be separated by therapy taking into account the dosage paradigm, timing, sex of the subjects and their gonadal hormone status. Several studies have demonstrated that beta-estradiol has indeed potency to protect neurons from seizure-induced damage. Additional studies are required to further elucidate the effects, exact conditions, and especially mechanisms of action of beta-estradiol in seizure-induced neuroprotection since new specific SERM may help to avoid some undesirable effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18537772     DOI: 10.2174/157488908784534577

Source DB:  PubMed          Journal:  Recent Pat CNS Drug Discov        ISSN: 1574-8898


  6 in total

Review 1.  Hormonal therapy for epilepsy.

Authors:  Scott J Stevens; Cynthia L Harden
Journal:  Curr Neurol Neurosci Rep       Date:  2011-08       Impact factor: 5.081

2.  A rat model of epilepsy in women: a tool to study physiological interactions between endocrine systems and seizures.

Authors:  Helen E Scharfman; Gauri H Malthankar-Phatak; Daniel Friedman; Patrice Pearce; Daniel P McCloskey; Cynthia L Harden; Neil J Maclusky
Journal:  Endocrinology       Date:  2009-05-14       Impact factor: 4.736

Review 3.  The role of neurosteroids in the pathophysiology and treatment of catamenial epilepsy.

Authors:  Doodipala Samba Reddy
Journal:  Epilepsy Res       Date:  2009-04-29       Impact factor: 3.045

Review 4.  Neuroendocrine aspects of catamenial epilepsy.

Authors:  Doodipala Samba Reddy
Journal:  Horm Behav       Date:  2012-05-02       Impact factor: 3.587

5.  Myoinositol Attenuates the Cell Loss and Biochemical Changes Induced by Kainic Acid Status Epilepticus.

Authors:  Lia Tsverava; Tamar Lordkipanidze; Eka Lepsveridze; Maia Nozadze; Marina Kikvidze; Revaz Solomonia
Journal:  Biomed Res Int       Date:  2016-08-23       Impact factor: 3.411

6.  Diagnosis and management of catamenial seizures: a review.

Authors:  Alberto Verrotti; Claudia D'Egidio; Sergio Agostinelli; Carla Verrotti; Piero Pavone
Journal:  Int J Womens Health       Date:  2012-09-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.